MeSH D006950 - familial combined hyperlipidemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ezetimibe | Ezetimibe |  | 2017-06-12 |  |  |
| Glenmark Pharmaceuticals | Ezetimibe | Ezetimibe |  | 2015-06-26 |  |  |
| Ezetimibe, Simvastatin | Ezetimibe Simvastatin |  | 2019-06-27 |  |  | |
| Sandoz | Ezetimibe | Ezetimibe |  | 2017-06-12 |  |  |
| Organon | Ezetimibe, Atorvastatin | Liptruzet |  | 2013-05-03 | $519 M | Q4/23-Q3/24 |
| Ezetimibe, Simvastatin | Vytorin |  | 2004-07-23 | $111 M | Q4/23-Q3/24 | |
| Ezetimibe | Zetia | 2022-01-25 | 2002-10-25 | $307 M | Q4/23-Q3/24 | |
| Aurobindo Pharma | Ezetimibe | Ezetimibe |  | 2017-08-25 |  |  |
| Ezetimibe, Simvastatin | Ezetimibe Simvastatin |  | 2020-12-17 |  |  | |
| Dr Reddys Laboratories | Ezetimibe, Simvastatin | Ezetimibe Simvastatin |  | 2017-04-26 |  |  |
| Rising Pharmaceuticals | Ezetimibe | Ezetimibe |  | 2019-04-26 |  |  |
| Zydus Therapeutics | Ezetimibe | Ezetimibe |  | 2017-06-12 |  |  |
| Alkem Laboratories | Ezetimibe | Ezetimibe |  | 2017-12-21 |  |  |
| Ezetimibe, Simvastatin | Ezetimibe Simvastatin |  | 2017-12-22 |  |  | |
| Apotex | Ezetimibe | Ezetimibe |  | 2017-06-12 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/2
Phase 2
0%0/0
Phase 3
67%2/3
Approved: 2Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use